Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Prices IPO, Targets $65M in Gross Proceeds

NEW YORK (GenomeWeb News) – Veracyte today priced its initial public offering of 5 million shares at $13 per share.

The South San Francisco, Calif.-based firm is expected to begin trading today on the Nasdaq Global Market under the symbol "VCYT." It will realize gross proceeds of $65 million from the offering, though the underwriters of the IPO have a 30-day option to purchase 750,000 additional shares to cover any over-allotments.

Veracyte launched its first commercial products, the Afirma Thyroid FNA Analysis test, in early 2011. It combines cytopathology with the firm's Afirma Gene Expression Classifier gene expression test, which includes a 142-gene signature, for assessing thyroid nodule fine needle aspirate biopsies that are neither clearly benign nor malignant based on cytology review.

In a preliminary prospectus the firm said that it planned to use around $20 million of the proceeds for sales and marketing activities, including expansion of its sales force, $20 million for R&D, and the remainder for general and administrative expenses.

Morgan Stanley, Leerink Swann, William Blair, and Cowen & Co., were underwriters on the offering.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.